Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only,
option for the treatment of leukemia. However, GVHD rate was still high after haploidentical
HSCT.
It was found in our previous study that CD4/CD8>=1.16、CD56bright NK>1.9×106/kg in the graft
was associated with higher risk of developing acute Graft-versus-host Disease (GVHD).
The study hypothesis:
Risk stratification-directed low-dose glucocorticoid prophylaxis for acute GVHD after
unmanipulated haploidentical blood and marrow transplantation can reduce the incidence of
acute GVHD